Tango Therapeutics Inc

In a Stage 4 decline, TNGX exhibits a clear sequence of lower highs and lower lows under bearish continuation patterns. Short-term weakness is confirmed by downtrending EMAs and failed rallies into resistance, making current conditions favorable to sell. Execution is recommended on rallies into the 9/21 EMA zone, where rejection at resistance can be anticipated.

• ↑Phase 2 data shows 92% ORR and 90% six-month PFS in PDAC
• ↑Analysts maintain 12 Buy ratings with a $41.50 average price target
• ↓Negative earnings yield and low book-to-price indicate overvaluation risk